Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Cash (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Change in Cash data on record, last reported at -$9.3 million in Q3 2025.

  • For Q3 2025, Change in Cash fell 172.13% year-over-year to -$9.3 million; the TTM value through Sep 2025 reached -$10.2 million, up 41.24%, while the annual FY2024 figure was -$3.3 million, 94.05% up from the prior year.
  • Change in Cash reached -$9.3 million in Q3 2025 per SGMO's latest filing, down from $13.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $46.9 million in Q2 2021 and bottomed at -$58.6 million in Q1 2022.
  • Average Change in Cash over 5 years is -$5.4 million, with a median of -$8.4 million recorded in 2021.
  • Peak YoY movement for Change in Cash: plummeted 601.64% in 2022, then skyrocketed 225.19% in 2024.
  • A 5-year view of Change in Cash shows it stood at $1.9 million in 2021, then surged by 206.26% to $5.9 million in 2022, then tumbled by 292.54% to -$11.3 million in 2023, then soared by 124.02% to $2.7 million in 2024, then crashed by 442.88% to -$9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$9.3 million in Q3 2025, $13.2 million in Q2 2025, and -$16.7 million in Q1 2025.